

References

S-60

1. CMS Online Manual Pub.100-3, National Coverage Determination (NCD) for Artificial Hearts and Related Devices. Section 20.9.
2. Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Heart Failure Guidelines. *American Heart Association*. 2013 doi: 10.1161/CIR.0b013e31829e8776.
3. Fukamachi K, Shiose A, Massiello A, et al. Preload Sensitivity in Cardiac Assist Devices. *The Annals of Thoracic Surgery*. 2013;95(1):373-380.
4. PROTECT II: A prospective, multi-center, randomized controlled trial of the Impella Recover LP 2.5 System versus intra-aortic balloon pump (IABP) in patients undergoing non emergent high risk PCI. Clinical trials.gov.
5. Griffith B et al. The RECOVER I: A Multicenter Prospective Study of Impella 5.0/LD for Postcardiotomy Circulatory Support. *J Thorac Cardiovasc Surg*. 2013;145:548-554.
6. Lemaire A, Anderson MB, Prendergast T, et al. Outcome of the Impella Device for Acute Mechanical Circulatory Support. *Innovations*. 2013;8(1):12-16.
7. Dangas GD, Kini SK, Shama SK, et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). *Am J Cardiol*. 2014;113(2):222-228.
8. Henriques JP, Ouweneel DM, Naidu SS, et al. Evaluating the learning curve in the prospective randomized clinical trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: A prespecified subanalysis of the PROTECT II study. *Am Heart J*. 2014; 167:472-479.
9. Lemaire A, Anderson MB, Lee Ly, et al. The Impella Device for Acute Mechanical Circulatory Support in Patients in Cardiogenic Shock. *Annals Thor Surgery*. 2014; 97(1):133-138.
10. Maini B, Scotti DJ, Gregory D. Health economics of percutaneous hemodynamic support in the treatment of high-risk cardiac patients: A systematic appraisal of the literature. *Expert Rev*. 2014; 4: e1-14.
11. Impella® 2.5 with the automated Impella® Controller: Instructions for use & clinical reference manual. Abiomed®. Danvers, MA. 2013.
12. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction circulation; A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines.
13. Kovacic JC, Kini A, Banerjee S, et al. Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump: a sub-study of the PROTECT II trial. *J Interv Cardiol*. 2015; 28(1):32-40.
14. Aryana A, Gearoid O'Neill P, Gregory D, et al. Procedural and clinical outcomes after catheter ablation of unstable ventricular tachycardia supported by a percutaneous left ventricular assist device. Abstract. *Heart Rhythm*. 2014; 11(7):1122-1130.

15. Demirozu ZT, Hernandez R, Mallidi HR, et al. HeartMate II left ventricular assist device implantation in patients with advanced hepatic dysfunction. *J Card Surg.* 2014; 29:419–423.
16. Reddy YM, Chinitz L, Mansour M, et al. Percutaneous left ventricular assist devices in ventricular tachycardia ablation: multicenter experience. *Circ Arrhythm Electrophysiol.* 2014; 7(2):244-250.
17. Cook JA, Shah KB, Quader MA, et al. The total artificial heart. *J Thorac Dis.* 2015;2172-2180.
18. Tsiouris A, Paone G, Neme HW, et al. Short and long term outcomes of 200 patients supported by continuous-flow left ventricular assist devices. *World J Cardiol.* 2015;792-800.
19. VanderPluym CJ, Fynn-Thompson F, Blume ED. Ventricular assist devices in children: Progress with an orphan device application. *Circulation.* 2014;1530-1537.
20. Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS Clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. *AHA.* 2015;7-26.
21. Acharya D. Ventricular Assist Device in Acute Myocardial Infarction. *Journal of the American College of Cardiology.* 2016;67(16): 1781-1880.
22. Chen S. Outpatient Outcomes of Pediatric Patients with Left Ventricular Assist Devices. *American Society of Artificial Internal Organs.* 2016; 163-168.
23. Muthiah K. Longitudinal structural, functional, and cellular myocardial alterations with chronic centrifugal continuous-flow left ventricular assist device support. *The Journal of Heart and Lung Transplantation.* 2017;36(7): 722-731.
24. Rihal C. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care. *Journal of the American College of Cardiology.* 2015;65(19): 1-20.
25. Kovacic JC, Nguyen HT, Karajgikar R, et al. The Impella Recover 2.5 and TandemHeart ventricular assist devices are safe and associated with equivalent clinical outcomes in patients undergoing high-risk percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2013;82(1):E28-37.
26. Briasoulis A, Telila T, Palla M, et al. Meta-analysis of usefulness of percutaneous left ventricular assist devices for high-risk percutaneous coronary interventions. *Am J Cardiol.* 2016;118(3):369-375.
27. Romeo F, Acconcia MC, Sergi D, et al. Percutaneous assist devices in acute myocardial infarction with cardiogenic shock: Review, meta-analysis. *World J Cardiol.* 2016;8(1):98-111.
28. Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. *J Am Coll Cardiol.* 2017;69(3):278- 287.
29. Schreiber T, Wah Htun W, Blank N, et al. Real-world supported unprotected left main percutaneous coronary intervention with impella device; data from the USpella Registry. *Catheter Cardiovasc Interv.* 2017;90(4):576-581.
30. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of

Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*. 2017 136(6):e137-e161.